Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Mar 2026 Results presented in the Dyne Therapeutics Media Release.
23 Feb 2026 According to a Dyne Therapeutics media release, data from this study will be presented at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held Wednesday, March 11, 9:30 a.m. ET, in Orlando, FL, and virtually.
08 Dec 2025 According to a Dyne Therapeutics media release, company will host a conference call and webcast to discuss these updates, December 8, 2025, at 8:00 a.m.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com